Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- TNGX
- Price
- 12.35
- Stock movement down
- -1.09 (-9.28%)
- Company name
- Tango Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.44B
- Ent value
- 1.43B
- Price/Sales
- 21.59
- Price/Book
- 8.97
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 230.03%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TNGX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 21.59 |
| Price to Book | 8.97 |
| EV to Sales | 21.46 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 134.68M |
| EPS (TTM) | -0.91 |
| FCF per share (TTM) | -1.32 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 66.50M |
| Gross profit (TTM) | 65.32M |
| Operating income (TTM) | -110.33M |
| Net income (TTM) | -100.52M |
| EPS (TTM) | -0.91 |
| EPS (1y forward) | -1.29 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 98.23% |
| Operating margin (TTM) | -165.91% |
| Profit margin (TTM) | -151.15% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 58.34M |
| Net receivables | 0.00 |
| Total current assets | 163.78M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 53.99M |
| Total assets | 210.14M |
| Accounts payable | 2.23M |
| Short/Current long term debt | 34.76M |
| Total current liabilities | 18.44M |
| Total liabilities | 50.10M |
| Shareholder's equity | 160.03M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -145.81M |
| Capital expenditures (TTM) | 950.00K |
| Free cash flow (TTM) | -146.76M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -62.81% |
| Return on Assets | -47.83% |
| Return on Invested Capital | -61.62% |
| Cash Return on Invested Capital | -89.97% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 11.53 |
| Daily high | 11.65 |
| Daily low | 10.37 |
| Daily Volume | 2.19M |
| All-time high | 17.30 |
| 1y analyst estimate | 13.25 |
| Beta | 1.72 |
| EPS (TTM) | -0.91 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 30 Mar 2026 |
Downside potential
Loading...
Downside potential data
| TNGX | S&P500 | |
| Current price drop from All-time high | -28.61% | -0.89% |
| Highest price drop | -93.64% | -19.00% |
| Date of highest drop | 8 May 2025 | 8 Apr 2025 |
| Avg drop from high | -70.38% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 315 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.44B
Marketcap category
Small-cap
Description
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Employees
155
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page